SEC Form 4 · accession 0001562180-16-002821
Intersect ENT, Inc. · XENT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Stambaugh
Officer — VP Clinical Affairs
Period of report
Jul 18, 2016
Accepted (ET)
Jul 19, 2016 · 6:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001271214
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 18, 2016 | M | 5,000 | $0.48 | A | 29,000 | D | |
| Common StockF2 | Jul 18, 2016 | S | 5,000 | $15.3286 | D | 24,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $0.48 | Jul 18, 2016 | M | 3,062 | D | — | Nov 16, 2016 | Common Stock | 3,062 | 0 | D |
| Stock Option (right to buy)F4 | $0.48 | Jul 18, 2016 | M | 1,938 | D | — | Aug 21, 2017 | Common Stock | 1,938 | 14,693 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.27 to $15.39, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4.
- F3The shares subject to the option are immediately exercisable. 1/48th of the shares subject to the option vest monthly over 48 months beginning October 23, 2007.
- F4The shares subject to the option are immediately exercisable. 1/48th of the shares subject to the option vest monthly over 48 months beginning August 22, 2007.